Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
Akari Therapeutics to Present at the 2026 Biotech Showcase
Akari Therapeutics (NASDAQ:AKTX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $1.00 price target on the stock.
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial